3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
